| 1. |
Scheaffer, A.N. Proposed usage of animal tissue culture terms (revised 1978). Usage of vertebrate cell, tissue and organ culture
terminology. In Vitro, 1979; 15(9): 649–653.
|
| |
| 2. |
Brenneman, D.E., et al. Protective peptides that are orally active and mechanistically nonchiral. J. Pharmacol. Exp. Ther., 2004; 309(3): 1190–1197.
|
| |
| 3. |
Pilzer, I., and Gozes, I. A splice variant to PACAP receptor that is involved in spermatogenesis is expressed in astrocytes.
Ann. NY Acad. Sci., 2006; 1070: 484–490.
|
| |
| 4. |
Romijn, H.J., et al. Nerve outgrowth, synaptogenesis and bioelectric activity in fetal rat cerebral cortex tissue cultured
in serum-free, chemically defined medium. Brain Res., 1981; 254(4): 583–589.
|
| |
| 5. |
Brenneman, D.E., et al. Complex array of cytokines released by vasoactive intestinal peptide. Neuropeptides, 2003; 37(2): 111–119.
|
| |
| 6. |
Dangoor, D., et al. Novel extended and branched N-terminal analogs of VIP. Regul. Pept., 2006; 137(1–2): 42–49.
|
| |
| 7. |
Offen, D., et al. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: Relevance to neuroprotection
in Parkinson’s disease. Brain Res., 2000; 854(1–2): 257–262.
|
| |
| 8. |
Davidson, A., Moody, T.W., and Gozes, I. Regulation of VIP gene expression in general. Human lung cancer cells in particular.
J. Mol. Neurosci., 1996; 76(2): 99–110.
|
| |
| 9. |
Moody, T.W., et al. (N-stearyl, norleucine17)VIP hybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
J. Mol. Neurosci., 2002; 18(1–2): 29–35.
|
| |
| 10. |
Gozes, Y., et al. Conditioned media from activated lymphocytes maintain sympathetic neurons in culture. Brain Res., 1982; 282(1): 93–97.
|
| |
| 11. |
Brenneman, D.E., and Gozes, I. A femtomolar-acting neuroprotective peptide. J. Clin. Invest., 1996; 97(10): 2299–2307.
|
| |
| 12. |
Bassan, M., et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide.
J. Neurochem., 1999; 72(3): 1283–1293.
|
| |
| 13. |
Gozes, I., et al. NAP: Research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).
CNS Drug Rev., 2005; 11(4): 353–368.
|
| |
| 14. |
Gozes, I., et al. Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide. Proc. Natl. Acad. Sci. USA, 1996; 93(1): 427–432.
|
| |
| 15. |
Visochek, L., et al. PolyADP-ribosylation is involved in neurotrophic activity. J. Neurosci., 2005; 25(32): 7420–7428.
|
| |
| 16. |
Divinski, I., et al. Peptide neuroprotection through specific interaction with brain tubulin. J. Neurochem., 2006; 98(3): 973–984.
|
| |
Loading...